An Open-Label, Multi-Centre Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T Cells in Patients With Advanced Non-Small Cell Lung Cancer

Conditions

Lung

Phase I

Volunteers
Health Professionals

What is the purpose of this trial?

This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterize the safety and clinical activity autologous clonal neoantigen reactive T cells (cNeT) administered intravenously in adults with advanced non-small cell lung cancer (NSCLC).

Find out more about who can participate in this trial

Trial with
Achilles Therapeutics
Start Date
10/05/2022
End Date
07/01/2023

For more information about this study, contact:

Laura Leary

laura.leary@yale.edu

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Michael Hurwitz, MD, PhD
Associate Professor of Internal Medicine (Medical Oncology)

Sub-Investigators

Last Updated
12/22/2022
Study HIC
#2000029536

An Open-Label, Multi-Centre Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T Cells in Patients With Advanced Non-Small Cell Lung Cancer

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information